Copaxone is a brand name of glatiramer, approved by the FDA in the following formulation(s):
COPAXONE (glatiramer acetate - injectable; subcutaneous)
Manufacturer: TEVA
Approval date: February 12, 2002
Strength(s): 20MG/ML [RLD]
Has a generic version of Copaxone been approved?
No. There is currently no therapeutically equivalent version of Copaxone available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Copaxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Copolymer-1 improvements in compositions of copolymers
Patent 5,981,589
Issued: November 9, 1999
Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
Assignee(s): Yeda Research and Development Co., Ltd.
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014
- May 24, 2014
Copolymer-1 improvements in compositions of copolymers
Patent 6,054,430
Issued: April 25, 2000
Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
Assignee(s): Yeda Research and Development Co., Ltd.
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014
- May 24, 2014
Copolymer-1 improvements in compositions of copolymers
Patent 6,342,476
Issued: January 29, 2002
Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
Assignee(s): Yeda Research & Development Company Limited
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014✓
- May 24, 2014
Copolymer-1 improvements on compositions of copolymers
Patent 6,362,161
Issued: March 26, 2002
Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
Assignee(s): Yeda Research & Development Company Limited
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014✓
- May 24, 2014
Copolymer-1 improvements in compositions of copolymers
Patent 6,620,847
Issued: September 16, 2003
Inventor(s): Eliezer; Konfino & Michael; Sela & Dvora; Teitelbaum & Ruth; Arnon
Assignee(s): Yeda Research and Development Co., Ltd.
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014✓
- May 24, 2014
Copolymer-1 improvements in compositions of copolymers
Patent 6,939,539
Issued: September 6, 2005
Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
Assignee(s): Yeda Research & Development
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014✓
- May 24, 2014
Copolymer-1 improvements in compositions of copolymers
Patent 7,199,098
Issued: April 3, 2007
Inventor(s): Konfino; Eliezer & Sela; Michael & Teitelbaum; Dvora & Arnon; Ruth
Assignee(s): Yeda Research and Development Co., Ltd.
The present invention relates to an improved composition of copolymer-1 comprising copolymer-1 substantially free of species having a molecular weight of over 40 kilodaltons.Patent expiration dates:
- May 24, 2014✓
- May 24, 2014
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- February 27, 2012 - INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS
See also...
- Copaxone Consumer Information (Drugs.com)
- Copaxone Consumer Information (Wolters Kluwer)
- Copaxone injection Consumer Information (Cerner Multum)
- Copaxone Advanced Consumer Information (Micromedex)
- Copaxone AHFS DI Monographs (ASHP)
- Glatiramer Consumer Information (Wolters Kluwer)
- Glatiramer injection Consumer Information (Cerner Multum)
- Glatiramer Subcutaneous Advanced Consumer Information (Micromedex)
- Glatiramer Acetate AHFS DI Monographs (ASHP)
No comments:
Post a Comment